VTYX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ventyx Biosciences (VTYX) is not a suitable buy for a beginner, long-term investor at this time. The stock is set to be acquired by Eli Lilly for $14 per share in cash, which caps its upside potential. With no significant catalysts, weak financial performance, and no trading signals from Intellectia Proprietary Trading Signals, holding the stock is the most logical action.
The MACD is negative and contracting, indicating a bearish momentum. RSI is neutral at 76.686, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot point of $13.97, with resistance at $14.007 and support at $13.947. However, the technical indicators do not suggest a strong buying opportunity.
Hedge funds have significantly increased their buying activity by 427.27% over the last quarter, which could indicate institutional confidence.
The acquisition by Eli Lilly for $14 per share limits any upside potential. Analysts have downgraded the stock to Neutral with price targets aligning with the acquisition price. Financial performance is weak, with declining net income and EPS. No recent news or congress trading data to act as a catalyst.
In Q3 2025, revenue remained at $0 with no growth. Net income dropped by 35.24% YoY to -$22.83 million, and EPS declined by 36% YoY to -$0.32. Gross margin remained at 0%. The financials indicate poor performance and no growth trends.
Analysts have downgraded the stock to Neutral with price targets reduced to $14, reflecting the acquisition price. This suggests limited upside and no further growth expectations.
